Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents results from an ongoing Phase I/II trial evaluating ADCT-602, a CD22 targeting antibody-drug conjugate (ADC) bound to the pyrrolobenzodiazepine (PBD) toxin, in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) (NCT03698552). Overall, ADCT-602 appears to be efficacious, with patients showing evidence of clinical activity and achieving measurable residual disease (MRD)-negative remission. The safety profile of ADCT-602 is also encouraging, with no significant toxicities observed so far. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.